Verici Dx is positioned directly within a growing market for transplant diagnostics, with a particular focus on kidney transplantation and molecular monitoring.
The global immunological risk assessment transplant market is estimated at $2.34 billion in 2026 and is projected to reach $5.39 billion by 2036, representing a compound annual growth rate of 8.7%. The expansion reflects increasing use of molecular testing, compatibility assessment and post-transplant surveillance as transplant centres look for more precise ways to assess rejection risk and graft health.
Kidney transplantation is especially relevant to Verici Dx. Kidney procedures are expected to account for 47% of the market in 2026, making them the largest transplant segment covered by the report.
Verici Dx is highlighted as a specialist in kidney transplant diagnostics. Its approach centres on molecular monitoring designed to support assessment of transplant patients after surgery. That gives the company a clear position within a market that is moving towards more detailed molecular surveillance. Molecular assays are expected to represent 41% of the market in 2026. Their role is becoming more important because they can support high-resolution testing and non-invasive monitoring of graft health. This is directly aligned with Verici Dx’s focus.
Reagents and assays are projected to account for 63% of the product market in 2026, reflecting the fact that testing is required across donor assessment, recipient evaluation and ongoing monitoring after transplantation.
Verici Dx also stands apart through its narrower focus on kidney transplantation. Larger competitors operate across HLA typing, antibody testing, compatibility assessment and multiple organ transplant categories. Verici Dx is more concentrated, giving it a clearer specialist position but also making successful adoption within kidney transplant centres particularly important.
Verici Dx Plc (LON:VRCI) is developing a complementary suite of proprietary, leading-edge tests forming a kidney transplant diagnostics platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.
